What's Happening?
Arrowhead Pharmaceuticals has presented new long-term efficacy and safety data for its investigational RNA interference therapeutic, plozasiran, at the American College of Cardiology's 75th Annual Scientific Session. The data, derived from a two-year
open-label extension study, showed significant reductions in triglyceride levels among patients with severe hypertriglyceridemia. The study reported an 83% median reduction in triglycerides, with 96% of patients achieving levels below 500 mg/dL, a threshold linked to increased risk of acute pancreatitis. The treatment also demonstrated favorable improvements in atherogenic lipoproteins and maintained a consistent safety profile. Plozasiran targets apolipoprotein C-III, a key regulator of triglyceride metabolism, aiming to reduce triglyceride levels and restore lipid balance.
Why It's Important?
The findings underscore plozasiran's potential as a therapeutic solution for patients with hypertriglyceridemia, a condition associated with increased risk of acute pancreatitis and cardiovascular diseases. The significant reduction in triglyceride levels could lead to better management of these risks, offering a new treatment avenue for patients with limited options. The study's results also highlight the promise of RNA interference technology in addressing complex metabolic disorders, potentially paving the way for broader applications in treating other genetic conditions. Arrowhead's progress with plozasiran could influence future regulatory approvals and market strategies in the pharmaceutical industry.
What's Next?
Arrowhead Pharmaceuticals plans to complete its ongoing Phase 3 clinical studies, SHASTA-3, SHASTA-4, and MUIR-3, by mid-2026. The company intends to submit a supplemental New Drug Application to the U.S. FDA by the end of 2026, aiming for regulatory approval to market plozasiran for severe hypertriglyceridemia. The company also plans to seek approvals from additional global regulatory authorities. These steps could lead to the commercial availability of plozasiran, potentially transforming the treatment landscape for hypertriglyceridemia and related conditions.
